FDA approves Kalydeco to treat rare form of cystic fibrosis

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm